Low-dose CT Screening and Smoking Cessation: Separate and Joint Associations with Mortality among Ever-Smokers Eligible for Lung Cancer Screening
- Journal
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (Q1)
- Published
- 13 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Huan Wang, Clara Frick, Sha Sha, Dominic Edelmann, Megha Bhardwaj, Hermann Brenner
- PMID
- 43025700
- DOI
- 10.1016/j.jtho.2026.106251
Why clinicians should know about it
- Picked for Pulmonary and Respiratory Medicine (paper of the day, 18 November 2026): Lung cancer screening and cessation outcomes inform respiratory prevention
Abstract
BACKGROUND: Smoking cessation intervention is increasingly recognized as a core component of high-quality lung cancer screening (LCS). However, real-world evidence that compares the health effects of low-dose CT (LDCT) screening, smoking cessation, and their combination among screening-eligible current smokers remains limited. METHODS: We conducted a post-hoc analysis of data of the National Lung Screening Trial (NLST), defining recent quitting as smoking cessation within 2 years before enrolment as a proxy for cessation occurring close to screening initiation. Cox proportional hazards models were used to quantify associations of screening allocation and smoking cessation with LC-specific and all-cause mortality. RESULTS: Among 31,560 continuous smokers and recent quitters included in the analysis, 7,197 (22.8%) died from any cause during a median follow-up of 12.3 years. Of 30,915 participants included in cause-specific analyses, 1,783 (5.8%) died from LC. Among current smokers eligible for LCS, LDCT was associated with 12% lower LC mortality than chest radiography (CXR) (HR, 0.88; 95% CI, 0.79-0.97), but no significant reduction of all-cause mortality (HR, 0.98; 95% CI, 0.93-1.03). In the CXR arm, recent quitting was associated with substantially lower LC and all-cause mortality than continued smoking (HRs, 0.62 and 0.68; 95% CIs, 0.51-0.76 and 0.62-0.75, respectively), with similar reductions observed among recent quitters in the LDCT arm. CONCLUSIONS: For screening-eligible current smokers, recent quitting was associated with substantially larger reductions in LC and all-cause mortality than those associated with LDCT screening. These findings reinforce the importance of integrating effective smoking cessation interventions into LCS programs.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.